Compare Range Nuclear Renaissance ETF (NUKZ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Range Nuclear Renaissance ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Range Nuclear Renaissance ETF trades at $57.5 (market cap $668.48M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 11.2× Range Nuclear Renaissance ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 23 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NUKZ | SYRE | |
|---|---|---|
Market Cap | $668.48M | $7.52B |
Volume | 55,573 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $108.92 |
52-Week Low | $58.42 | $22.18 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUKZ (Range Nuclear Renaissance Index ETF) trades at $60.37, showing minimal daily movement (+0.18%). The technical picture remains bearish with moving averages signaling strong selling pressure, though oscillators suggest neutral momentum. Recent industry developments include Google's 3.6 GW nuclear deal with Constellation Energy and record global nuclear power generation, creating positive sector tailwinds despite the ETF's current technical weakness.
The nuclear energy sector faces both significant catalysts and challenges. Strong demand from AI data centers and federal support for new projects provide growth opportunities, while supply chain bottlenecks and execution risks remain concerns. With the ETF trading near support levels, investors are watching for fundamental improvements to drive price recovery.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
